文献速递脑血管病

西洛他唑联合双联抗血小板治疗启动时机与卒中复发的关系:CSPS.com 试验事后分析

Association of Timing for Starting Dual Antiplatelet Treatment With Cilostazol and Recurrent Stroke: A CSPS.com Trial Post Hoc Analysis.
PubMed 文献 · Neurology · 2022-01-24

该事后分析纳入 1879 例非心源性缺血性卒中患者,按启动西洛他唑联合阿司匹林或氯吡格雷的双联抗血小板治疗时间分为 8-14 天、15-28 天和 29-180 天三组。结果显示,15-28 天组和 29-180 天组双联治疗较单药治疗显著降低缺血性卒中复发风险,而 8-14 天组无显著差异;严重或危及生命出血在三组中均无显著差异。

要点

  • 卒中后 15-28 天启动西洛他唑双联治疗,年化复发率 1.5% 对单药 4.9%,校正 HR 0.34。
  • 卒中后 29-180 天启动双联治疗,年化复发率 1.9% 对单药 4.4%,校正 HR 0.27。
  • 卒中后 8-14 天启动双联治疗与单药复发风险相似,年化率均为 4.5%,HR 1.02。

核心结论

  • 卒中后 15-180 天启动西洛他唑联合阿司匹林或氯吡格雷的长期双联抗血小板治疗,较 8-14 天启动更有效预防卒中复发,且不增加出血风险。
  • 该研究提供 II 级证据:急性非心源性卒中患者服用阿司匹林或氯吡格雷时,在卒中后 15-180 天加用西洛他唑可降低复发性缺血性卒中风险。

研究设计与样本

  • 随机对照试验的事后亚组分析,患者于卒中后 8-180 天随机接受阿司匹林或氯吡格雷单药,或西洛他唑联合阿司匹林或氯吡格雷。
  • 共纳入 1879 例患者,按启动试验治疗时间分为 8-14 天组(498 例)、15-28 天组(467 例)和 29-180 天组(914 例)。
  • 主要疗效结局为首次复发性缺血性卒中,安全性结局包括严重或危及生命出血。

主要发现

  • 缺血性卒中复发在试验治疗与三分类组间存在显著交互作用。
  • 15-28 天组:双联治疗年化复发率 1.5% 对单药 4.9%,校正 HR 0.34(95% CI 0.12-0.95)。
  • 29-180 天组:双联治疗年化复发率 1.9% 对单药 4.4%,校正 HR 0.27(95% CI 0.12-0.63)。
  • 8-14 天组:双联治疗与单药年化复发率均为 4.5%,HR 1.02(95% CI 0.51-2.04)。
  • 严重或危及生命出血在三组中双联治疗与单药治疗相似:8-14 天组粗 HR 0.22(95% CI 0.03-1.88),15-28 天组 1.07(95% CI 0.15-7.60),29-180 天组 0.76(95% CI 0.24-2.39)。

关键数值与推荐

  • 15-28 天组双联治疗较单药降低缺血性卒中复发风险,校正 HR 0.34(95% CI 0.12-0.95)。
  • 29-180 天组双联治疗较单药降低缺血性卒中复发风险,校正 HR 0.27(95% CI 0.12-0.63)。
  • 8-14 天组双联治疗与单药复发风险相似,HR 1.02(95% CI 0.51-2.04)。
  • 严重或危及生命出血在各时间亚组双联与单药间均无显著差异。

临床怎么用

  • 对于急性非心源性缺血性卒中服用阿司匹林或氯吡格雷的患者,在卒中后 15-180 天加用西洛他唑可能降低复发性缺血性卒中风险(II 级证据)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Long-term treatment with the combination of cilostazol with aspirin or clopidogrel showed a lower risk of stroke recurrence compared to aspirin or clopidogrel alone after high-risk noncardioembolic ischemic stroke in a randomized trial. We aimed to determine whether the effect of the dual medication compared to monotherapy on risk of recurrent ischemic stroke differs according to timing of starting medication after stroke onset. METHODS: In a subanalysis of the randomized controlled trial, patients between 8 and 180 days after stroke onset were randomly assigned to receive aspirin or clopidogrel alone or a combination of cilostazol with aspirin or clopidogrel. They were divided into 3 groups according to the timing of starting trial treatment: between 8 and 14 days after stroke onset (8-14 days group), between 15 and 28 days after stroke onset (15-28 days group), and between 29 and 180 days after stroke onset (29-180 days group). The primary efficacy outcome was the first recurrence of ischemic stroke. Safety outcomes included severe or life-threatening bleeding. RESULTS: Of 1,879 patients, 498 belonged to the 8-14 days group, 467 to the 15-28 days group, and 914 to the 29-180 days group. There was a significant treatment-by-subgroup interaction for the recurrence of ischemic stroke between trial treatment and trichotomized groups. The recurrence of ischemic stroke was less common with dual therapy than with monotherapy in the 15-28 days group (annualized rate 1.5% vs 4.9%, respectively; adjusted hazard ratio 0.34 [95% CI 0.12-0.95]) and the 29-180 days group (1.9% vs 4.4%, respectively; 0.27 [0.12-0.63]) and similarly common in the 8-14 days group (4.5% for both; 1.02 [0.51-2.04]). Severe or life-threatening bleeding occurred similarly between patients on dual therapy and those on monotherapy in any of the trichotomized groups (crude hazard ratio 0.22 [95% CI 0.03-1.88] in the 8-14 days group, 1.07 [0.15-7.60] in the 15-28 days group, and 0.76 [0.24-2.39] in the 29-180 days group). DISCUSSION: Long-term dual antiplatelet therapy using cilostazol starting 15-180 days after stroke onset, compared to therapy started 8-14 days after onset, was more effective for secondary stroke prevention than monotherapy without increasing hemorrhage risk. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov NCT01995370; UMIN Clinical Trials Registry 000012180. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with acute noncardioembolic stroke taking either aspirin or clopidogrel, the addition of cilostazol 15-180 days after stroke onset decreases the risk of recurrent ischemic stroke.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Toyoda K, Omae K, Hoshino H, et al. Association of Timing for Starting Dual Antiplatelet Treatment With Cilostazol and Recurrent Stroke: A CSPS.com Trial Post Hoc Analysis. Neurology. 2022. PMID: 35074890. doi:10.1212/WNL.0000000000200064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。